FDG-PET in Early AD Diagnosis

Medical Clinics of North America

Volumn 97, Issue 3, 2013, Pages 485-494

  Chew, Jessica ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Dementia; Fluorodeoxyglucose; Multimodal imaging; PET; Prodromal diagnosis; Progression

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN SCINTISCANNING; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

AGED; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASES; BLOOD GLUCOSE; BRAIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENERGY METABOLISM; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 84877027646     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.12.016     Document Type: Review

References (50)

1. Alzheimer's Association 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012, 8(2):131-168.
2. Chu L.W. Alzheimer's disease: early diagnosis and treatment. Hong Kong Med J 2012, 18(3):228-237.
3. Galimberti D., Scarpini E. Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 2011, 4(4):203-216.
4. Rountree S.D., Chan W., Pavlik V.N., et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009, 1(2):7.
5. Wilkinson D., Schindler R., Schwam E., et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28(3):244-251.
6. Peters O., Lorenz D., Fesche A., et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012, 16(6):544-548.
7. Minoshima S., Giordani B., Berent S., et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997, 42(1):85-94.
8. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286(17):2120-2127.
9. Lehman V.T., Carter R.E., Claassen D.O., et al. Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. Clin Nucl Med 2012, 37(8):721-726.
10. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):280-292.
11. Jack C.R., Albert M.S., Knopman D.S., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):257-262.
12. Amieva H., Le Goff M., Millet X., et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008, 64(5):492-498.
13. Mortimer J.A., Petersen R.C. Detection of prodromal Alzheimer's disease. Ann Neurol 2008, 64(5):479-480.
14. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9(11):1118-1127.
15. Morbelli S., Drzezga A., Perneczky R., et al. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging 2012, 33(11):2533-2550.
16. Kantarci K., Senjem M.L., Lowe V.J., et al. Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol 2010, 31(7):1247-1253.
17. Mosconi L., Silverman D.S. FDG PET in the evaluation of mild cognitive impairment and early dementia. PET in the evaluation of Alzheimer's disease and related disorders 2009, 49-65. Springer, New York. D. Silverman (Ed.).
18. Yakushev I., Hammers A., Fellgiebel A., et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009, 44(1):43-50.
19. Morinaga A., Ono K., Ikeda T., et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord 2010, 30(4):285-292.
20. Boeve B.F. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):S41-S44.
21. Kasanuki K., Iseki E., Fujishiro H., et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci 2012, 314(1-2):111-119.
22. Foster N.L., Heidebrink J.L., Clark C.M., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130(Pt 10):2616-2635.
23. Kanda T., Ishii K., Uemura T., et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008, 35(12):2227-2234.
24. Poljansky S., Ibach B., Hirschberger B., et al. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci 2011, 261(6):433-446.
25. Dukart J., Mueller K., Horstmann A., et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One 2011, 6(3):e18111.
26. Silverman D.H. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004, 45(4):594-607.
27. Teune L.K., Bartels A.L., de Jong B.M., et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010, 25(14):2395-2404.
28. Johnson K.A., Fox N.C., Sperling R.A., et al. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2(4):a006213.
29. Lo R.Y., Hubbard A.E., Shaw L.M., et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011, 68(10):1257-1266.
30. Caroli A., Frisoni G.B. Alzheimer's Disease Neuroimaging I. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 2010, 31(8):1263-1274.
31. Galluzzi S., Geroldi C., Amicucci G., et al. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol 2012, 16:16.
32. Landau S.M., Harvey D., Madison C.M., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75(3):230-238.
33. Kim S.H., Seo S.W., Yoon D.S., et al. Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: a five-year longitudinal study. Dement Geriatr Cogn Disord 2010, 29(3):213-223.
34. Morbelli S., Piccardo A., Villavecchia G., et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging 2010, 37(1):36-45.
35. Chen K., Ayutyanont N., Langbaum J.B., et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011, 56(1):52-60.
36. Torosyan N., Mason K., Dahlbom M., et al. Prognostic value of PET scans for predicting rate of functional decline of normal and MCI subjects over 3 years. J Nucl Med 2012, 53(S1):92P.
37. Mason K., Torosyan N., Dahlbom M., et al. Value of FDG-PET in predicting rate of subsequent cognitive decline among cognitively normal and mildly impaired subjects. J Nucl Med 2012, 53(Suppl 1):461P.
38. Jack C.R., Petersen R.C., Xu Y.C., et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49(3):786-794.
39. Geroldi C., Rossi R., Calvagna C., et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006, 77(11):1219-1222.
40. Devanand D.P., Pradhaban G., Liu X., et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007, 68(11):828-836.
41. Cavallin L., Loken K., Engedal K., et al. Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiol 2012, 53(3):318-323.
42. Galton C.J., Patterson K., Xuereb J.H., et al. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000, 123(Pt 3):484-498.
43. Chow N., Aarsland D., Honarpisheh H., et al. Comparing hippocampal atrophy in Alzheimer's dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2012, 34(1):44-50.
44. O'Brien J.T. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007, 80(Spec No 2):S71-S77.
45. Herholz K. Perfusion SPECT and FDG-PET. Int Psychogeriatr 2011, 23(Suppl 2):S25-S31.
46. Torosyan N., Silverman D.H. Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. Semin Nucl Med 2012, 42(6):415-422.
47. Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG-00088R). 2004. Available at: Accessed November 15, 2012. http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx%3FNCAId=104.
48. Silverman D.H., Gambhir S.S., Huang H.W., et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002, 43(2):253-266.
49. Moulin-Romsee G., Maes A., Silverman D., et al. Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol 2005, 12(4):254-263.
50. Henderson T.A. The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectr 2012, 17(4):176-206.